medigraphic.com
ISSN 2992-7749 (Electronic)
ISSN 2992-7897 (Print)
Órgano Oficial de difusión científica de la Asociación Mexicana de Cirujanos de Columna A. C.

2026, Number 1

<< Back Next >>

Cir Columna 2026; 4 (1)

Efficacy of tranexamic acid in reducing perioperative blood loss and transfusion rates in multilevel spinal surgery: a retrospective cohort study

Robles OMJ, Robles ORE, Salinas CAN, Vargas CM

Language: Spanish
References: 29
Page: 12-18
PDF size: 270.96 Kb.


ABSTRACT

Introduction: complex spinal surgeries are often associated with significant blood loss, which can increase morbidity, the need for transfusions, and prolonged hospital stays. Tranexamic acid (ATX) is an antifibrinolytic agent used in various surgical specialties to reduce bleeding. Objective: to evaluate the efficacy of tranexamic acid in reducing intraoperative and postoperative bleeding and the need for transfusions in patients undergoing thoracolumbar or lumbosacral spine surgery with multilevel instrumentation. Material and methods: a retrospective cohort study was conducted in 67 patients who underwent surgery between March 2022 and March 2024. Two groups were compared: one hereceived ATX (n = 23) and the other did not (n = 44). Clinical, transfusion, and hematological variables were analyzed. Results: no statistically significant differences were found in intraoperative blood loss volume or transfusion rates between the groups. However, the group treated with ATX showed slightly higher postoperative hemoglobin and hematocrit levels, with less variability. Conclusion: although the use of ATX did not show a significant reduction in blood loss or transfusions, it could promote greater postoperative hemodynamic stability. Prospective, multicenter studies with larger sample sizes are needed to confirm these findings.


REFERENCES

  1. Neilipovitz DT, Elgafy H, Bransford RJ, McGuire RA.Tranexamic acid for major spinal surgery. Eur Spine J. 2004; 13: S62-S65.

  2. Yi S, Yoon DH, Kim KN, Kim SH, Shin HC. Postoperativespinal epidural hematoma: risk factor and clinicaloutcome. Yonsei Med J. 2006; 47: 326-332.

  3. Willner D, Spennati V, Stohl S, Tosti G, Aloisio S, BilottaF. Spine surgery and blood loss: systematic review ofclinical evidence. Anesth Analg. 2016; 123: 1307-1315.

  4. Hofmann A, Ozawa S, Farrugia A, Farmer SL, ShanderWA. Economic considerations on transfusion medicineand patient blood management. Best Pract Res ClinAnaesthesiol. 2013; 27: 59-68.

  5. Zollo RA, Eaton MP, Karcz M, Pasternak R, Glance LG.Blood transfusion in the perioperative period. Best PractRes Clin Anaesthesiol. 2012; 26: 475-484.

  6. Fletcher ND, Marks MC, Asghar JK, Hwang SW,Sponseller PD, Harms Study Group, et al. Developmentof consensus based best practice guidelines forperioperative management of blood loss in patientsundergoing posterior spinal fusion for adolescentidiopathic scoliosis. Spine Deform. 2018; 6: 424-429.

  7. Ker K, Prieto-Merino D, Roberts I. Systematic review,meta-analysis and meta-regression of the effect oftranexamic acid on surgical blood loss. Br J Surg. 2013;100: 1271-1279.

  8. Henry DA, Carless PA, Moxey AJ, O’Connell D,Stokes BJ, McClelland B, et al. Anti-fibrinolytic use forminimising perioperative allogeneic blood transfusion.Cochrane Database Syst Rev. 2011; 3: CD001886.

  9. McCormack PL. Tranexamic acid: a review of its usein the treatment of hyperfibrinolysis. Drugs. 2012; 72:585-617.

  10. Melander B, Gliniecki G, Granstrand B, HanshoffG. Biochemistry and toxicology of amikapron; theantifibrinolytically active isomer of AMCHA. ActaPharmacol Toxicol (Copenh). 1965; 22: 340-352.

  11. Nuttall GA, Horlocker TT, Santrach PJ, Oliver WC Jr,Dekutoski MB, Bryant S. Predictors of blood transfusionsin spinal instrumentation and fusion surgery. Spine (PhilaPa 1976). 2000; 25: 596-601. doi: 10.1097/00007632-200003010-00010

  12. Farrokhi MR, Kazemi AP, Eftekharian HR, Akbari K.Efficacy of prophylactic low dose of tranexamic acidin spinal fixation surgery: a randomized clinical trial. JNeurosurg Anesthesiol. 2011; 23: 290-296.

  13. Winter SF, Santaguida C, Wong J, Fehlings MG.Systemic and topical use of tranexamic acid in spinalsurgery: a systematic review. Global Spine J. 2016; 6:284-295.

  14. Hinev A, Paunov S. Mini-incision muscle-sparing lumbarapproach to the kidney, the renal pelvis and the upperureter. Urology. 2006; 68: 224.

  15. Cuellar JM, Yoo A, Tovar N, Coelho PG, Jimbo R,Vandeweghe S, et al. The effects of Amicar and TXAon lumbar spine fusion in an animal model. Spine (PhilaPa 1976). 2014; 39: E1132-E1137.

  16. Choi HY, Hyun SJ, Kim KJ, Jahng TA, Kim HJ. Effectivenessand safety of tranexamic acid in spinal deformity surgery. JKorean Neurosurg Soc. 2017; 60: 75-81.

  17. Lin ZX, Woolf SK. Safety, efficacy, and cost-effectivenessof tranexamic acid in orthopedic surgery. Orthopedics.2016; 39: 119-130.

  18. Zufferey P, Merquiol F, Laporte S, Decousus H,Mismetti P, Auboyer C, et al. Do antifibrinolytics reduceallogeneic blood transfusion in orthopedic surgery?Anesthesiology. 2006; 105: 1034-1046.

  19. Lin JD, Lenke LG, Shillingford JN, Laratta JL, Tan LA,Fischer CR, et al. Safety of a high-dose tranexamic acidprotocol in complex adult spinal deformity: analysis of100 consecutive cases. Spine Deform. 2018; 6: 189-194.

  20. Huang F, Wu D, Ma G, Yin Z, Wang Q. The use oftranexamic acid to reduce blood loss and transfusion inmajor orthopedic surgery: a meta-analysis. J Surg Res.2014; 186: 318-327.

  21. Zhao Y, Xi C, Xu W, Yan J. Role of tranexamicacid in blood loss control and blood transfusionmanagement of patients undergoing multilevel spinesurgery. Medicine. 2021; 100: e24678. doi: 10.1097/md.0000000000024678

  22. Abdou M, Kwon J, Kim HJ, Lee B, Choi YS, Moon SH, etal. Tranexamic acid and intraoperative and postoperativeaccumulative bleeding in elective degenerative spinesurgery. Yonsei Med J. 2022; 63: 927. doi: 10.3349/ymj.2022.0163

  23. Li X, Jiao G, Li J, Ji W, Hao Z, Gong F, et al.Combined use of tranexamic acid and rivaroxabanin posterior/transforaminal lumbar interbody fusionsurgeries. Global Spine J. 2021; 13: 1229-1237. doi:10.1177/21925682211024556

  24. Lotan R, Lengenova S, Rijini N, Hershkovich O.Intravenous tranexamic acid reduces blood loss inmultilevel spine surgeries. J Am Acad Orthop Surg.2022; 31: e226-e230. doi: 10.5435/jaaos-d-22-00738

  25. Honda A, Iizuka Y, Michihata N, Uda K, Mieda T,Takasawa E, et al. Effect of intraoperative tranexamicacid on perioperative major hemorrhage requiringtransfusion. Global Spine J. 2022; 14: 804-811. doi:10.1177/21925682221123317

  26. Wang Q, Liu J, Fan R, Chen Y, Yu H, Bi Y, et al.Tranexamic acid reduces postoperative blood lossof degenerative lumbar instability with stenosis. EurSpine J. 2013; 22: 2035–2038. doi: 10.1007/s00586-013-2836-z

  27. Li ZJ, Fu X, Xing D, Zhang HF, Zang JC, Ma XL. Istranexamic acid effective and safe in spinal surgery?Eur Spine J. 2013; 22: 1950-1957. doi: 10.1007/s00586-013-2774-9

  28. Dong W, Tang Y, Lei M, Ma Z, Zhang X, Shen J, etal. The effect of perioperative sequential applicationof multiple doses of tranexamic acid on postoperativeblood loss after PLIF. Int J Surg. 2024; 110: 2122-2133.doi: 10.1097/JS9.0000000000001083

  29. Zhang D, Wu X, Kong Q, Wang Y, Zhang B, Feng P,et al. Prospective randomized controlled trial on theeffectiveness of low-dose and high-dose intravenoustranexamic acid in reducing perioperative blood loss insingle-level minimally invasive transforaminal lumbarinterbody fusion. Zhongguo Xiu Fu Chong Jian WaiKe Za Zhi. 2022; 36: 439-445. doi: 10.7507/1002-1892.202112015




2020     |     www.medigraphic.com